Showing results (251-260 of 260) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 260 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemC M Balch, S J Soong, J E Gershenwald, et al.
The New England Journal of Medicine|October 7, 1982
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanomaU Veronesi, J Adamus, C Aubert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2014
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trialF Perrone, F Nuzzo, F Di Rella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2012
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE studyF Nuzzo, C Gallo, S Lastoria, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patientsA Puccini, F Grillo, M Fassan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Frontiers in Endocrinology|May 13, 2024
Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlationSimona F Madeo, Luca Zagaroli, Sara Vandelli, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|February 26, 2022
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenarioL Cantini, G Mentrasti, G L Russo, et al.
Pageof 26